Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Simple item page
dc.conference.dateAPR 10-13, 2019
dc.conference.titleEuropean Lung Cancer Congress (ELCC)
dc.contributor.authorOwonikoko, T. K.
dc.contributor.authorKim, H. R.
dc.contributor.authorGovindan, R.
dc.contributor.authorReady, N.
dc.contributor.authorReck, M.
dc.contributor.authorPeters, S.
dc.contributor.authorDakhil, S. R.
dc.contributor.authorNavarro, A.
dc.contributor.authorRodriguez-Cid, J.
dc.contributor.authorSchenker, M.
dc.contributor.authorLee, J. S.
dc.contributor.authorGutierrez, V.
dc.contributor.authorPercent, I.
dc.contributor.authorMorgensztern, D.
dc.contributor.authorFairchild, J.
dc.contributor.authorBaudelet, C.
dc.contributor.authorPark, K.
dc.contributor.authoraffiliation[Owonikoko, T. K.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
dc.contributor.authoraffiliation[Kim, H. R.] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Div Med Oncol,Dept Internal Med, Seoul, South Korea
dc.contributor.authoraffiliation[Govindan, R.] Washington Univ, Sch Med, St Louis, MO USA
dc.contributor.authoraffiliation[Morgensztern, D.] Washington Univ, Sch Med, St Louis, MO USA
dc.contributor.authoraffiliation[Ready, N.] Duke Univ, Med Ctr, Durham, NC USA
dc.contributor.authoraffiliation[Reck, M.] Krankenhaus Grosshansdorf, Thorac Oncol, Grosshansdorf, Germany
dc.contributor.authoraffiliation[Peters, S.] CHU Vaudois, Multidisciplinary Oncol Ctr, Lausanne, Switzerland
dc.contributor.authoraffiliation[Dakhil, S. R.] Canc Ctr Kansas, Wichita, KS USA
dc.contributor.authoraffiliation[Navarro, A.] Vall dHebron Univ Hosp, Barcelona, Spain
dc.contributor.authoraffiliation[Rodriguez-Cid, J.] Ctr Oncol, Med Sur, Mexico City, DF, Mexico
dc.contributor.authoraffiliation[Schenker, M.] Ctr Oncol Sf Nectarie, Craiova, Romania
dc.contributor.authoraffiliation[Lee, J. S.] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
dc.contributor.authoraffiliation[Gutierrez, V.] Hosp Carlos Haya Malaga, Malaga, Spain
dc.contributor.authoraffiliation[Percent, I.] Florida Canc Specialists, Punta Gorda, FL USA
dc.contributor.authoraffiliation[Fairchild, J.] Bristol Myers Squibb, Princeton, NJ USA
dc.contributor.authoraffiliation[Baudelet, C.] Bristol Myers Squibb, Princeton, NJ USA
dc.contributor.authoraffiliation[Park, K.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Haematol Oncol, Seoul, South Korea
dc.contributor.funderBristol-Myers Squibb
dc.date.accessioned2025-01-07T12:16:13Z
dc.date.available2025-01-07T12:16:13Z
dc.date.issued2019-04-01
dc.identifier.doi10.1093/annonc/mdz094
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753419302595/pdf
dc.identifier.urihttps://hdl.handle.net/10668/24385
dc.identifier.wosID478089000208
dc.issue.number2
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.page.number77-77
dc.publisherOxford univ press
dc.rights.accessRightsopen access
dc.titleNivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number30
dc.wostypeMeeting Abstract

Files

Collections

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía